Arixtra is used to prevent blood clots forming in patients who are recovering from orthopaedic or abdominal surgery. Arixtra is also used to treat blood clots once they have formed. Arixtra contains the medication fondaparinux sodium, a synthetic compound which helps prevent blood clots forming in blood vessels. This type of blood clot, also called deep venous thrombosis, or DVT, can occur in patients who are confined to bed after hip or knee surgery.
Your doctor may have prescribed Arixtra for another reason. Ask your doctor if you have any questions about why Arixtra has been prescribed for you.
Arixtra is not addictive.
This medicine is available only with a doctor's prescription.
You should not be given Arixtra if you have any of the following conditions;
Do not use Arixtra if you have an allergy to it or any of the ingredients listed at the end of this leaflet.
Symptoms of an allergic reaction to Arixtra may include skin rash, itchiness, shortness of breath, or difficulty breathing.
Do not use Arixtra if you are pregnant or intend to become pregnant.
Arixtra is not recommended for use during pregnancy, unless you and your doctor or pharmacist have discussed the risks and benefits involved.
Do not use Arixtra if you are breast-feeding or plan to breast-feed.
It is not known whether Arixtra passes into human breast milk.
Do not use Arixtra after the expiry date (EXP) printed on the pack.
If you use this medicine after the expiry date has passed, it may not work as well as it should.
Do not use Arixtra if the packaging is torn or shows signs of tampering.
If you are not sure whether you should start using Arixtra, talk to your doctor or pharmacist.
Tell your doctor or pharmacist if you have allergies to:
Tell your doctor or pharmacist if you are pregnant or intend to become pregnant.
Your doctor or pharmacist will discuss the possible risks and benefits of using Arixtra during pregnancy.
Tell your doctor or pharmacist if you are breast-feeding or plan to breast-feed.
Your doctor or pharmacist will discuss the possible risks and benefits of using Arixtra during breast-feeding.
Tell your doctor or pharmacist if you have or have had any medical conditions, especially the following:
Tell your doctor or pharmacist if you are elderly or have a low body weight (less than 50kg) as you may be at increased risk of bleeding if you are given Arixtra.
It is recommended that your doctor monitor's your blood platelets at the beginning and end of your treatment with Arixtra.
If you have not told your doctor or pharmacist about any of the above, tell them before you start using Arixtra.
Tell your doctor or pharmacist if you are taking/using any other medicines, including any that you buy without a prescription from your pharmacy, supermarket or health food shop.
Some medicines and Arixtra may interfere with each other.
Your doctor or pharmacist may have more information on medicines to be careful with or to avoid while using Arixtra.
The usual dose of Arixtra is 2.5 mg given once a day, starting after your operation. Arixtra may be given for up to 31 days.
Arixtra is given to you as a subcutaneous injection (an injection just under the skin). Arixtra should not be given as an intramuscular injection (an injection into the muscle). The injections can be given by a doctor or nurse, or you may be taught how to give the injections to yourself.
Instructions on how to use the Arixtra syringe are contained in the package insert in each Arixtra carton.
Your doctor or pharmacist has information on how to recognise and treat an overdose. Ask your doctor or pharmacist if you have any concerns.
If you think that you or anyone else may have been given too much Arixtra, immediately telephone your doctor or contact the Poisons Information Centre (telephone 131126) for advice on overdose management or go to accident and emergency at your nearest hospital.
Do this even if there are no signs of discomfort or poisoning.
Tell any other doctors, dentists, and pharmacists who are treating you that you are using Arixtra.
If you are about to be started on any new medicine, tell your doctor, dentist or pharmacist that you are using Arixtra.
Immediately tell your doctor if you develop the following:
These may be signs that a blood clot has formed.
If you have epidural or spinal anaesthesia (a pain killing injection around the spinal cord), tell your doctor or nurse immediately if you have back pain, numbness or weakness in the legs, or problems with bowel or bladder function.
Do not give Arixtra to anyone else, even if they have the same condition as you.
Do not use Arixtra to treat any other complaints unless your doctor or pharmacist tells you to.
Arixtra helps most people at risk of blood clots following surgery, but it may have unwanted side effects in some people. All medicines can have side effects. Sometimes they are serious, most of the time they are not. You may need medical treatment if you get some of the side effects.
These side effects of Arixtra are usually mild.
These may be signs of serious side effects. You may need urgent medical attention. Serious side effects are rare.
The following side effects may be identified by tests performed by your doctor:
Other side effects not listed above may occur in some patients. Tell your doctor or pharmacist if you notice anything that is making you feel unwell.
Do not be alarmed by this list of possible side effects.
You may not experience any of them.
Arixtra will normally be stored in the pharmacy or on the hospital ward. The injection should be kept at room temperature (less than 25 degrees C).
If your doctor or pharmacist tells you to stop using Arixtra or the injections have passed their expiry date, ask your pharmacist what to do with any that are left over.
Arixtra comes as a pre-filled safety syringe, in pack sizes of 2 pre-filled syringes.
Arixtra is supplied in Australia by;
GlaxoSmithKline Australia Pty Ltd
Level 4, 436 Johnston Street
Abbotsford, Victoria, 3067
Arixtra has the following registration No:
2.5 mg - AUST R 80279
This leaflet was prepared on
14 March 2013